Janux Corp (JANX) Long-Term Debt to Capital Ratio

Janux Therapeutics - graphic logo of issuer JANX

The Janux Therapeutics (JANX) price chart demonstrates a long-term debt structure, with the indicator standing at 0.02. Drug development progress here is accelerated by robotics and AI, although final tests require medical supervision. Janux Therapeutics (JANX) is developing a unique TRACT system for targeted tumor strikes. Since there are no commercial sales, the market capitalization relies on scientific achievements and the prospects of future contracts.

Long-Term Debt to Equity: Janux Therapeutics (JANX) for 07/04/2022 - 10/31/2026

Analytical breakdowns for Janux Therapeutics

- market price and analyst price targets:
Market Price Janux Therapeutics Inc|JANX - Price Target Chart
- market capitalization details:
Market Capitalization Janux Therapeutics, Inc.|JANX - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Janux Therapeutics|JANX - Company Book Value|Market-to-Book Ratio januxrx.com|JANX - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Janux Therapeutics|JANX - Long-Term Debt to Equity|Current Liabilities to Capital januxrx.com|JANX - Company Aggregate Debts|Debt to Net Assets Janux Therapeutics, Inc.|JANX - Company Long-Term Liabilities|Short-Term Debt Janux Therapeutics|Intermediate Coverage Ratio januxrx.com
- company profitability and valuation multiples indicators:
JANX - Net Profit
Summary company analysis:JANX - Janux Therapeutics Inc
Brand item of Janux Pharma

To minimize default risks, it is critical for investors to assess the stability of the issuer's financing structure. This ratio is calculated as the proportion of liabilities with a maturity of over one year to equity, and this long-term debt load chart helps determine the balance between borrowed funds and the autonomy of Janux Therapeutics (JANX) when implementing costly clinical drug trials.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Immunocore PLC (IMCR)|Arcus Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital ZYME (Zymeworks Inc.)|TNGX - Long-Term Debt to Equity Ratio|IOVA - Long-Term Debt to Equity|Long-Term Liabilities to Capital Immatics NV|Xencor Corp (XNCR) - Long-Term Debt to Equity|CMPX (Compass Therapeutics Corp) - Long-Term Debt to Equity|Long-Term Debt to Equity Replimune Group, Inc.|Long-Term Liabilities to Capital lyell.com LYEL|Long-Term Debt to Capital IPHA|pyxisoncology.com (PYXS) - Long-Term Indebtedness to Equity|Compugen - Long-Term Debt to Equity Ratio|IO Biotech Inc. (IOBT) - Long-Term Liabilities to Capital|STRO: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient INKT (minktherapeutics.com)|HOWL: Long-Term Debt to Capital|IMMX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALX Oncology Holdings|Long-Term Debt to Equity Ratio cuebiopharma.com (CUE)|Long-Term Debt to Equity PDS Biotechnology (PDSB)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|MAIA Biotechnology, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Liminatus Pharma Inc. LIMN|LVTX - Long-Term Debt to Equity|NXTC (NextCure Corporation) - Long-Term Debt to Capital Ratio|leaptx.com (LPTX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Intensity Therapeutics, Inc. (INTS)|Long-Term Debt to Equity Ratio SNSE|TOVX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc